Literature DB >> 15472533

Regulatory T cells: peace keepers in the gut.

Matthieu Allez1, Lloyd Mayer.   

Abstract

The mucosa-associated lymphoid tissue (MALT) has the task of protecting the host from pathogens while maintaining the integrity of the gut. Immune responses are tightly regulated such that there is tolerance of nonpathogenic bacteria as well as dietary antigens present in the intestinal lumen. The failure to control these responses leads to a disruption in tolerance, which has been proposed as one mechanism involved in the development of inflammatory bowel disease (IBD). Different mechanisms are involved in the control of immune responses in the intestinal tract, including active suppression by regulatory T cells. Distinct subsets of regulatory T cells coexist in the intestinal mucosa, which is a fertile environment for their growth. Most of these are defined by their phenotype and/or their ability to produce regulatory cytokines such as interleukin-10 and transforming growth factor-beta A lack of activation and/or expansion of regulatory cells could play a role in the uncontrolled inflammation seen in IBD. Regulatory T cells may be activated by cytokines, and their inductive phase may be antigen-driven. There are limited data relating to the true surface interactions regulating the activation of these cells. Most of the CD4 regulatory T cells (Tr1, Th3, and CD4 CD25+) are thought to interact with dendritic cells. Subsets of regulatory T cells (such as CD8 TrE cells) may recognize antigens presented by intestinal epithelial cells. A better understanding of the mechanisms by which these regulatory T cells are expanded and/or activated in the intestinal mucosa may provide clues as how to use them as a novel therapeutic tool in the treatment of patients with IBD. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2004        PMID: 15472533     DOI: 10.1097/00054725-200409000-00027

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  29 in total

Review 1.  Epithelia: lymphocyte interactions in the gut.

Authors:  Stephanie Dahan; Franziska Roth-Walter; Paul Arnaboldi; Shradha Agarwal; Lloyd Mayer
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

2.  In vivo Treg suppression assays.

Authors:  Creg J Workman; Lauren W Collison; Maria Bettini; Meenu R Pillai; Jerold E Rehg; Dario A A Vignali
Journal:  Methods Mol Biol       Date:  2011

3.  Oligoclonal expansions of mucosal T cells in Crohn's disease predominate in NKG2D-expressing CD4 T cells.

Authors:  M Camus; S Esses; B Pariente; L Le Bourhis; C Douay; V Chardiny; I Mocan; K Benlagha; E Clave; A Toubert; L Mayer; M Allez
Journal:  Mucosal Immunol       Date:  2013-08-14       Impact factor: 7.313

4.  Defect in CEACAM family member expression in Crohn's disease IECs is regulated by the transcription factor SOX9.

Authors:  Giulia Roda; Stephanie Dahan; Laura Mezzanotte; Alessandra Caponi; Franziska Roth-Walter; David Pinn; Lloyd Mayer
Journal:  Inflamm Bowel Dis       Date:  2009-07-27       Impact factor: 5.325

5.  Relationship between various Chinese medicine types and T-cell subsets in patients with ulcerative colitis.

Authors:  Ting-min Chang; Xiu-min Li; Xi-de Zhao
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

6.  Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells.

Authors:  Irina V Pinchuk; Ellen J Beswick; Jamal I Saada; Gushyalatha Boya; David Schmitt; Gottumukkala S Raju; Julia Brenmoehl; Gerhard Rogler; Victor E Reyes; Don W Powell
Journal:  Gastroenterology       Date:  2011-03-02       Impact factor: 22.682

7.  Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.

Authors:  E Quévrain; M A Maubert; C Michon; H Sokol; P Seksik; F Chain; R Marquant; J Tailhades; S Miquel; L Carlier; L G Bermúdez-Humarán; B Pigneur; O Lequin; P Kharrat; G Thomas; D Rainteau; C Aubry; N Breyner; C Afonso; S Lavielle; J-P Grill; G Chassaing; J M Chatel; G Trugnan; R Xavier; P Langella
Journal:  Gut       Date:  2015-06-04       Impact factor: 23.059

Review 8.  Mesenchymal cells of the intestinal lamina propria.

Authors:  D W Powell; I V Pinchuk; J I Saada; Xin Chen; R C Mifflin
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

9.  Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease.

Authors:  B Szebeni; G Veres; A Dezsõfi; K Rusai; A Vannay; M Mraz; E Majorova; A Arató
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

10.  Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients.

Authors:  M Lorea Baroja; P V Kirjavainen; S Hekmat; G Reid
Journal:  Clin Exp Immunol       Date:  2007-06-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.